Similar articles

• Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer.

  Yilmaz A, Ernam D, Unsal E, Demirag F, Atikcan S, Taştepe I. Yilmaz A, et al. Arch Med Res. 2007 Oct;38(7):764-8. doi: 10.1016/j.arcmed.2007.04.005. Epub 2007 Jul 12. Arch Med Res. 2007. PMID: 17845896
• [P27 expression and survival in NSCLC].

  Hirabayashi H. Hirabayashi H. Nihon Rinsho. 2002 May;60 Suppl 5:263-6. Nihon Rinsho. 2002. PMID: 12101669 Review. Japanese. No abstract available.
• Artificial neural networks and logistic regression as tools for prediction of survival in patients with Stages I and II non-small cell lung cancer.

  Marchevsky AM, Patel S, Wiley KJ, Stephenson MA, Gondo M, Brown RW, Yi ES, Benedict WF, Anton RC, Cagle PT. Marchevsky AM, et al. Mod Pathol. 1998 Jul;11(7):618-25. Mod Pathol. 1998. PMID: 9688182
• First clinically useful marker for lung cancer identified.

  [No authors listed] [No authors listed] Oncology (Williston Park). 2003 May;17(5):737-8. Oncology (Williston Park). 2003. PMID: 12800797 No abstract available.
• [Oncogenes, differentiation markers and morphological criteria as prognostic parameters in non-small-cell bronchial carcinoma].

  Thomas M, Junker K. Thomas M, et al. Dtsch Med Wochenschr. 1997 Oct 24;122(43):1327-31. doi: 10.1055/s-2008-1047767. Dtsch Med Wochenschr. 1997. PMID: 9410698 Review. German. No abstract available.